$OHCS
Optimus Healthcare Services, Inc.

2024 Q3 Form 10-Q Financial Statement

#000121390024066846 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $384.8K $639.3K
YoY Change -15.2% 98.29%
Cost Of Revenue $74.06K $58.06K
YoY Change -7.13% -1.85%
Gross Profit $310.7K $581.2K
YoY Change -16.92% 120.79%
Gross Profit Margin 80.75% 90.92%
Selling, General & Admin $1.831M
YoY Change -31.96%
% of Gross Profit 314.96%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.409K $3.503K
YoY Change -56.15% 0.03%
% of Gross Profit 1.1% 0.6%
Operating Expenses $1.912M $1.831M
YoY Change 11.15% -31.96%
Operating Profit -$1.601M -$1.249M
YoY Change 18.95% -48.52%
Interest Expense -$200.7K
YoY Change -274.8%
% of Operating Profit
Other Income/Expense, Net -$205.1K -$200.7K
YoY Change -52.5% -53.46%
Pretax Income -$1.807M -$1.450M
YoY Change 1.6% -49.27%
Income Tax $993.00
% Of Pretax Income
Net Earnings -$1.807M -$1.451M
YoY Change 1.6% -49.27%
Net Earnings / Revenue -469.52% -226.98%
Basic Earnings Per Share -$0.04 -$0.03
Diluted Earnings Per Share -$0.04 -$0.03
COMMON SHARES
Basic Shares Outstanding 47.91M shares 45.79M shares
Diluted Shares Outstanding 47.88M shares 45.68M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.97K
YoY Change -89.99%
Cash & Equivalents $152.4K $12.76K
Short-Term Investments $19.21K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $602.4K
Other Receivables $0.00
Total Short-Term Assets $418.1K $634.3K
YoY Change -62.46% -32.95%
LONG-TERM ASSETS
Property, Plant & Equipment $28.82K $32.23K
YoY Change -64.14% -53.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $211.4K $228.7K
YoY Change -82.89% -80.82%
TOTAL ASSETS
Total Short-Term Assets $418.1K $634.3K
Total Long-Term Assets $211.4K $228.7K
Total Assets $629.5K $863.1K
YoY Change -73.21% -59.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.464M $1.341M
YoY Change 35.51% 20.45%
Accrued Expenses $1.719M $1.429M
YoY Change 157.59% 162.19%
Deferred Revenue
YoY Change
Short-Term Debt $2.136M
YoY Change 96.36%
Long-Term Debt Due $4.405M
YoY Change 31.94%
Total Short-Term Liabilities $9.842M $9.373M
YoY Change 35.6% 52.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.842M $9.373M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $9.973M $9.519M
YoY Change 32.75% 48.58%
SHAREHOLDERS EQUITY
Retained Earnings -$33.81M -$32.01M
YoY Change 27.01% 28.82%
Common Stock $47.91K $45.80K
YoY Change 19.86% 14.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.340M -$8.652M
YoY Change
Total Liabilities & Shareholders Equity $629.5K $863.1K
YoY Change -73.21% -59.64%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$1.807M -$1.451M
YoY Change 1.6% -49.27%
Depreciation, Depletion And Amortization $3.409K $3.503K
YoY Change -56.15% 0.03%
Cash From Operating Activities -$238.7K
YoY Change -77.01%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 179.9K
YoY Change -77.81%
NET CHANGE
Cash From Operating Activities -238.7K
Cash From Investing Activities 0.000
Cash From Financing Activities 179.9K
Net Change In Cash -58.81K
YoY Change 139.55%
FREE CASH FLOW
Cash From Operating Activities -$238.7K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40116769 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39967476 shares
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2024Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43256140 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45678620 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-261849
dei Entity Registrant Name
EntityRegistrantName
OPTIMUS HEALTHCARE SERVICES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0181535
dei Entity Address Address Line1
EntityAddressAddressLine1
1400 Old Country Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 306
dei Entity Address City Or Town
EntityAddressCityOrTown
Westbury
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11590
dei City Area Code
CityAreaCode
(516)
dei Local Phone Number
LocalPhoneNumber
806-4201
dei No Trading Symbol Flag
NoTradingSymbolFlag
true
dei Security12b Title
Security12bTitle
None
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47906664 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12764 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100319 usd
CY2024Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
602353 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
572707 usd
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
100000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19206 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33592 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
634323 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
806618 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
196519 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
224316 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32225 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39164 usd
CY2024Q2 us-gaap Assets
Assets
863067 usd
CY2023Q4 us-gaap Assets
Assets
1070098 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1341129 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1154309 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1429264 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1043270 usd
CY2024Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
133925 usd
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
135744 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4400000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
3915732 usd
CY2024Q2 ohcs Paycheck Protection Program Loan Current
PaycheckProtectionProgramLoanCurrent
4810 usd
CY2023Q4 ohcs Paycheck Protection Program Loan Current
PaycheckProtectionProgramLoanCurrent
5304 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
61378 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59765 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9372506 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8034124 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
146119 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
175344 usd
CY2023Q4 ohcs Paycheck Protection Program Loan Non Current
PaycheckProtectionProgramLoanNonCurrent
1592 usd
CY2024Q2 us-gaap Liabilities
Liabilities
9518625 usd
CY2023Q4 us-gaap Liabilities
Liabilities
8211060 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45794664 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45794664 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39967598 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39967598 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
45795 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
39968 usd
CY2023Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
550 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23302390 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22947709 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32007998 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30133916 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-8651705 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-7137581 usd
CY2024Q2 us-gaap Minority Interest
MinorityInterest
-3853 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-3381 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-8655558 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7140962 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
863067 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1070098 usd
CY2024Q2 us-gaap Revenues
Revenues
639303 usd
CY2023Q2 us-gaap Revenues
Revenues
322414 usd
us-gaap Revenues
Revenues
983768 usd
us-gaap Revenues
Revenues
594056 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
58061 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
59158 usd
us-gaap Cost Of Revenue
CostOfRevenue
120243 usd
us-gaap Cost Of Revenue
CostOfRevenue
139182 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
581242 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
263256 usd
us-gaap Gross Profit
GrossProfit
863525 usd
us-gaap Gross Profit
GrossProfit
454874 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
898352 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1183518 usd
us-gaap Share Based Compensation
ShareBasedCompensation
-233715 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2601461 usd
CY2024Q2 us-gaap Other General Expense
OtherGeneralExpense
443543 usd
CY2023Q2 us-gaap Other General Expense
OtherGeneralExpense
844196 usd
us-gaap Other General Expense
OtherGeneralExpense
909034 usd
us-gaap Other General Expense
OtherGeneralExpense
1730452 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
437375 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
600536 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
787107 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1027089 usd
CY2024Q2 us-gaap Professional Fees
ProfessionalFees
51392 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
62200 usd
us-gaap Professional Fees
ProfessionalFees
138024 usd
us-gaap Professional Fees
ProfessionalFees
203479 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1830662 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
2690450 usd
us-gaap Operating Expenses
OperatingExpenses
1600450 usd
us-gaap Operating Expenses
OperatingExpenses
5562481 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1249420 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2427194 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-736925 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5107607 usd
CY2023Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
288151 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
484268 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
573136 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
201596 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
114796 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
394604 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
218584 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-263857 usd
CY2023Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-32211 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
78510 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
942 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
6076 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
8000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-200654 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-431158 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1136653 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-705210 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1450074 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2858352 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1873578 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5812817 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
993 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2025 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
976 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2025 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1451067 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2860377 usd
us-gaap Net Income Loss
NetIncomeLoss
-1874554 usd
us-gaap Net Income Loss
NetIncomeLoss
-5814842 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
191 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
474 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
472 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
893 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-1450876 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-2859903 usd
us-gaap Profit Loss
ProfitLoss
-1874082 usd
us-gaap Profit Loss
ProfitLoss
-5813949 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1451067 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2860377 usd
us-gaap Net Income Loss
NetIncomeLoss
-1874554 usd
us-gaap Net Income Loss
NetIncomeLoss
-5814842 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45678620 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40116769 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43256140 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39967476 shares
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7140962 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
-15282 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
-1116786 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
411459 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
50215 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-423487 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-8234843 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
898352 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
132000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1451067 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-8655558 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1642522 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
725000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
206755 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1211188 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2954465 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2454044 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
136827 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
188795 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
994723 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2860377 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4267730 usd
us-gaap Net Income Loss
NetIncomeLoss
-1874554 usd
us-gaap Net Income Loss
NetIncomeLoss
-5814842 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6939 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7166 usd
us-gaap Share Based Compensation
ShareBasedCompensation
-233715 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2601461 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
78510 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-263857 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
484268 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
573136 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
184 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1215 usd
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-70354 usd
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-99298 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-14386 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
17524 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
186820 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
375043 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
715811 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-36675 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-365650 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2290232 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
936330 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
713622 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19552 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
203156 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
725000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
136827 usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
100000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
182000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
949800 usd
ohcs Payment Of Paycheck Protection Program Loan
PaymentOfPaycheckProtectionProgramLoan
2086 usd
ohcs Payment Of Paycheck Protection Program Loan
PaymentOfPaycheckProtectionProgramLoan
2479 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1819 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2314 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
278095 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1533180 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-87555 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-553896 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100319 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
751017 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12764 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197121 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
200700 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
976 usd
us-gaap Stock Issued1
StockIssued1
543459 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Optimus Healthcare Services, Inc. (formerly Between Dandelions, Inc., “Optimus”, “Company”) was initially organized under the laws of Florida on February 26, 1990, as Phoenix Management Associates, Inc. Over the ensuing years, the Company made a series of amendments to its Articles of Incorporation relating to authorization of various series of Preferred Shares and made a series of name changes. The current name of Optimus Healthcare Services, Inc. became effective with the State of Florida on January 24, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is dedicated to advancing access to clinical trial research through its portfolio company Clinical Research Alliance, Inc. (“CRA”), and until December 2023 when it discontinued operations of its early stage pharmacy operation, through its portfolio company Worker’s Health Rx (d/b/a “Vitality Rx”).</p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1990-02-26
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of equity issued for services, valuation of equity associated with convertible debt, the valuation of derivative liabilities, and the valuation of deferred tax assets. Actual results could differ from these estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in certificates of deposit, deposit accounts or treasury bills. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.</p>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12764 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100319 usd
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
0 usd
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
0 usd
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
815500 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2323772 usd
ohcs Expense Recovery Amount
ExpenseRecoveryAmount
2601461 usd
us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.50 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
75796664 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8590414 shares
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company entered into a lease agreement commencing on July 1, 2023 through June 30, 2026 for 2,153 square feet of office space located at One Dupont Street, Suite 112, Plainview, New York, 11803.
CY2024Q2 us-gaap Settlement Assets Current
SettlementAssetsCurrent
6100 usd
CY2024Q2 us-gaap Security Deposit
SecurityDeposit
5250 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
158 usd
us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.075 pure
us-gaap Payments For Rent
PaymentsForRent
47912 usd
us-gaap Payments For Rent
PaymentsForRent
61726 usd
CY2024Q2 us-gaap Payments For Rent
PaymentsForRent
24041 usd
CY2023Q2 us-gaap Payments For Rent
PaymentsForRent
30835 usd
CY2024Q2 ohcs Operating Lease Right Of Use Asset Office Lease
OperatingLeaseRightOfUseAssetOfficeLease
371832 usd
CY2023Q4 ohcs Operating Lease Right Of Use Asset Office Lease
OperatingLeaseRightOfUseAssetOfficeLease
371832 usd
CY2024Q2 ohcs Operating Lease Right Of Use Asset Equipment Lease
OperatingLeaseRightOfUseAssetEquipmentLease
5068 usd
CY2023Q4 ohcs Operating Lease Right Of Use Asset Equipment Lease
OperatingLeaseRightOfUseAssetEquipmentLease
5676 usd
CY2024Q2 ohcs Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
180381 usd
CY2023Q4 ohcs Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
153192 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
196519 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
224316 usd
CY2024Q2 ohcs Operating Lease Liability Office Lease
OperatingLeaseLiabilityOfficeLease
203196 usd
CY2023Q4 ohcs Operating Lease Liability Office Lease
OperatingLeaseLiabilityOfficeLease
229433 usd
CY2024Q2 ohcs Operating Lease Liability Equipment Lease
OperatingLeaseLiabilityEquipmentLease
4301 usd
CY2023Q4 ohcs Operating Lease Liability Equipment Lease
OperatingLeaseLiabilityEquipmentLease
5676 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
61378 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59765 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
146119 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
175344 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
35989 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
73215 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
74957 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
49677 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
233838 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
26341 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
207497 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12764 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100319 usd
CY2024Q2 ohcs Working Capital Deficit
WorkingCapitalDeficit
8738183 usd
CY2023Q4 ohcs Working Capital Deficit
WorkingCapitalDeficit
7227506 usd
us-gaap Net Income Loss
NetIncomeLoss
-1874554 usd
us-gaap Net Income Loss
NetIncomeLoss
-5814842 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1451067 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2860377 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32007998 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30133916 usd
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
815500 usd
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-37979 usd
CY2022Q4 us-gaap Loans Payable
LoansPayable
200000 usd
CY2022Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
100000 usd
CY2022Q4 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
3600000 usd
CY2022Q4 us-gaap Beneficial Interest
BeneficialInterest
100000 usd
CY2022Q4 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
3500000 usd
CY2022Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
3627927 usd
CY2022Q4 us-gaap Gain Loss On Sale Of Property
GainLossOnSaleOfProperty
127927 usd
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
100000 usd
us-gaap Liabilities Average Amount Outstanding
LiabilitiesAverageAmountOutstanding
100000 usd
CY2024Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
19880 usd
CY2023Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
19880 usd
CY2024Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
43784 usd
CY2023Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
43784 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
63664 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
63664 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31439 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24500 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32225 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39164 usd
CY2024Q2 us-gaap Depreciation
Depreciation
3503 usd
us-gaap Depreciation
Depreciation
6939 usd
CY2023Q2 us-gaap Depreciation
Depreciation
3502 usd
us-gaap Depreciation
Depreciation
6666 usd
CY2024Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
133925 usd
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
135744 usd
CY2020Q2 us-gaap Loans Receivable With Fixed Rates Of Interest1
LoansReceivableWithFixedRatesOfInterest1
145683 usd
CY2020Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
126546 usd
us-gaap Loans Receivable Description Of Variable Rate Basis
LoansReceivableDescriptionOfVariableRateBasis
The unforgiven portion of the PPP loan totaling $19,137 is payable over five years at an interest rate of 1%, with a deferral of payments for the first twelve months.
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4810 usd
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
4400000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
3915732 usd
CY2024Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0 usd
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
4400000 usd
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2200000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
394604 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
218584 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
201596 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
114796 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
484268 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
573136 usd
CY2024Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2023Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
288151 usd
CY2024Q1 ohcs Gross Proceeds
GrossProceeds
2000000 usd
CY2024Q1 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
350000 usd
ohcs Other Transaction Document Between The Parties For Liquidate Damages
OtherTransactionDocumentBetweenThePartiesForLiquidateDamages
197817 usd
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
3165066 usd
ohcs Percentage Of Outstanding Principal Rate
PercentageOfOutstandingPrincipalRate
0.12 pure
ohcs Agreements Liquidated Damages
AgreementsLiquidatedDamages
20000 usd
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
4861674 usd
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
4597817 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-263857 usd
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2000000 shares
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000 shares
CY2023 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
1275000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
0 usd
us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
1.25
ohcs Preferred Stock Voting Rightsshare
PreferredStockVotingRightsshare
1.25
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
9998899 shares
CY2020Q4 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
9998889 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2000000 shares
us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
0.52
CY2024Q2 us-gaap Share Price
SharePrice
0.52
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
2.5449 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0397 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9882500 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.43
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M28D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2000000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.52
ohcs Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Term Options Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingTermOptionsGranted
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3060000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.58
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8822500 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M4D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3222500 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M13D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2323772 usd
ohcs Share Based Compensation Reversal For Stock Cancellation
ShareBasedCompensationReversalForStockCancellation
2542205 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2205911 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
898352 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
994723 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3185801 usd
ohcs Percentage Of Restricted Stock Vest
PercentageOfRestrictedStockVest
0.25 pure
us-gaap Restricted Stock Expense
RestrictedStockExpense
0 usd
us-gaap Restricted Stock Expense
RestrictedStockExpense
395550 usd
CY2024Q2 us-gaap Restricted Stock Expense
RestrictedStockExpense
0 usd
CY2023Q2 us-gaap Restricted Stock Expense
RestrictedStockExpense
188795 usd
CY2024Q2 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
usd
CY2024Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Stock Issued1
StockIssued1
usd
CY2024Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001892025
dei Security Exchange Name
SecurityExchangeName
NONE

Files In Submission

Name View Source Status
0001213900-24-066846-index-headers.html Edgar Link pending
0001213900-24-066846-index.html Edgar Link pending
0001213900-24-066846.txt Edgar Link pending
0001213900-24-066846-xbrl.zip Edgar Link pending
ea0210668-10q_optimus.htm Edgar Link pending
ea021066801ex31-1_optimus.htm Edgar Link pending
ea021066801ex31-2_optimus.htm Edgar Link pending
ea021066801ex32-1_optimus.htm Edgar Link pending
ea021066801ex32-2_optimus.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ohcs-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
ohcs-20240630_cal.xml Edgar Link unprocessable
ohcs-20240630_def.xml Edgar Link unprocessable
ohcs-20240630_lab.xml Edgar Link unprocessable
ohcs-20240630_pre.xml Edgar Link unprocessable
ea0210668-10q_optimus_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable